

5 March 2025

## Argent BioPharma Ltd. (Argent BioPharma or the Company)

### Strategic Manufacturing Partnership with ECCPharm Limited

#### Highlights:

- **ECCPharm will provide all GMP product manufacturing and batch release services for Argent BioPharma's key cannabinoid therapies.**
- **Argent BioPharmato to operaitonally focus on core product clinical development, medical advancement, and regulatory expansion.**
- **ECCPharm to manufacture CannEpil® and CogniCann® for early patient access programs in Key EU countries, including Ireland, the UK, and Germany.**
- **Manufacturing operations will transition immediately from Argent's European GMP facilities to ECCPharm's EU-GMP-certified facility in North Macedonia.**
- **Collaboration on product manufacturting is set to minimise monthly operational costs for Argent alongside generating robust, increasing revenues for ECCPharm.**

Argent BioPharma Limited is pleased to announce a strategic manufacturing partnership with ECCPharm Limited (**ECC Pharm**), a leading EU-GMP-certified pharmaceutical manufacturer. Under the agreement, ECCPharm will take on full manufacturing and batch release responsibilities for Argent BioPharma's pioneering cannabinoid therapies—CannEpil® and CogniCann®—ensuring these treatments are available under early patient access programs in in Key EU countries, including Ireland, the UK, and Germany.

As part of the partnership, ECCPharm will implement a technology transfer (**Transfer**) to relocate manufacturing operations from Argent's current GMP-certified European facilities to its state-of-the-art facility in North Macedonia. All costs associacited with the Transfer will be borne by the Company. This move is designed to enhance production efficiency, ensure regulatory compliance, and support scalable manufacturing to meet the growing global patient demand. Argent BioPharma further confirms it will retain ownership of all current and furtuer R&D and Interlectual Propoerty rigths under the partnership.

This strategic partnership will allow ArgentBiopharma to focus its resources on its core expertise and intellectual property, in product clinical development and medical advancement. It will also deliver significant monthly operatiional cost reductions for Argent BioPharma and minimise monthly cashflow burn from running its own manufacturing facilities within Europe.

#### Product Focus:

##### **CannEpil® – Advanced Therapy for Refractory Epilepsy:**

CannEpil® is a clinically supported, cannabinoid-based treatment for patients with refractory epilepsy—those who have not benefited from traditional anti-epileptic drugs. Having human trials in Australia and Real World Data gathering over the years<sup>1</sup>, CannEpil® target is to be available under early patient access programs in key European markets.

##### **CogniCann® – A Potential Breakthrough in Neurodegenerative Diseases:**

CogniCann® is an investigational therapy targeting dementia, Alzheimer's disease, and potentially Parkinson's disease. Early clinical trial results in Australia have indicated improvements in cognitive function, behavior, and overall patient well-being<sup>2</sup>. With early patient use approved in Germany and Ireland—and expansion planned in the UK—CogniCann® stands as a promising candidate in the fight against neurodegenerative disorders.

<sup>1</sup> Refer to ASX Announcement dated 22 August 2022

<sup>2</sup> Refer to ASX Announcement dated 6 June 2022



**Roby Zomer, CEO and Managing Director commented:** *“This collaboration with ECCPharm represents a major milestone for our company. By leveraging ECCPharm’s manufacturing expertise, we secure a scalable, cost-effective production platform for CannEpil® and CogniCann®. This allows us to concentrate on our core mission—advancing clinical development and expanding regulatory approvals worldwide.”*

**ECCPharm’s CEO, Dimitar Miladinov commented:** *“We are proud to partner with Argent BioPharma to support the production of these specialised cannabinoid medicines. Our EU-GMP-certified facility is well-equipped to meet the increasing demand for high-quality, medical cannabis-based pharmaceuticals, and this agreement will further solidify our position as a leading contract manufacturing partner in the global market.”*

**Next Steps:**

The technology transfer process will commence immediately, with manufacturing at ECCPharm’s North Macedonian facility expected to begin in the coming months. Further updates on the partnership and the expansion of patient access programs will be communicated as developments progress.

—Ends—

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**About ECC Pharm**

ECCPharm is a leading EU-GMP-certified cannabinoid pharmaceutical company specializing in the development, manufacturing, and distribution of high-quality cannabinoid-based drugs across Europe. With state-of-the-art facilities and a commitment to stringent European pharmaceutical standards, ECCPharm ensures the delivery of safe and effective cannabinoid therapies. Through its strategic European subsidiaries, Medtradix and Cannaport, ECCPharm efficiently manages the wholesale distribution of cannabinoid-based pharmaceuticals, reinforcing its dedication to enhancing patient access and care across the continent.

**About Argent BioPharma**

Argent BioPharma Limited (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma’s robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases

Follow us through our social media channels:

LinkedIn: Argent BioPharma  
Twitter: @ArgentBioPharma  
Facebook: Argent BioPharma

**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)

